

Timing Prednisone Release Eased Stiffness in RA

BY MICHELE G. SULLIVAN

A modified-release formulation of prednisone reduced morning stiffness duration in patients with rheumatoid arthritis, according to data presented at the annual European Congress of Rheumatology.

The new formulation is designed to be taken at bedtime. The medication is released about 4 hours after ingestion, with the goal of adapting glucocorticoid drug release to the circadian rhythms of endogenous cortisol and symptoms of the disease, both of which have their peaks during the early morning hours. It has been theorized that morning glucocorticoid dosing only inadequately controls the circadian rhythm of RA symptoms in these patients, Prof. Frank Buttgerit, of Charité Medical University of Berlin, said in an interview.

"It's well known that symptoms of rheumatoid arthritis follow circadian rhythms and are typically most promi-

'The timing of systemic glucocorticoid therapy may be important with respect to the natural secretion of endogenous glucocorticoids as well as the control of symptoms.'

nent in the early morning hours," he said. "Therefore, the timing of systemic glucocorticoid therapy may be important with respect to the natural secretion of endogenous glucocorticoids as well as the control of symptoms."

Findings from earlier research conducted by Prof. Buttgerit and his associates involved a 3-month randomized, controlled trial of 288 patients with longstanding active rheumatoid arthritis (Lancet 2008;371:205-14).

The data he presented at EULAR concerned 219 patients who completed a new 9-month follow-on open-label trial of the same group, during which all patients took the modified-release formulation.

At baseline, the patients' mean age was 55 years; their mean duration of disease was 10 years. Patients who were randomized to the active group took a placebo tablet in the morning and the study drug in the evening. The comparator group took immediate-release prednisone in the morning and placebo in the evening. The prednisone dose was individually titrated (range, 3-10 mg/day).

The mean relative reduction of morning stiffness duration was significantly higher in the modified-release group than in the immediate-release group (23% vs. 0.4%). Patients taking the modified-release drug had a significantly greater decrease in duration of morning joint stiffness than did those taking the immediate-release tablet (44 vs. 23 fewer minutes of morning stiffness). Median levels of interleukin-6 were also reduced in the modified-release group compared with the immediate-release group (29% vs. 0%).

Adverse events led to premature discontinuation of the study drugs in 8% of patients in the modified-release group and 7% of those in the immediate-release group. The frequency of serious adverse events was low and similar in both groups (3% vs. 2%).

The combined results of the randomized and open-label trials, showed that in both groups, morning stiffness duration remained similarly low over the entire

study duration, he said. At 12 months, the reduction was somewhat greater in the group that had taken the modified-release formulation during both trials (55%) than among those who took the immediate-release during the first trial and the modified-release during the follow-on study (45%).

Among his expected conclusions is that "bedtime administration of prednisone via the new modified-release

tablet provides significantly greater efficacy for at least 12 months over conventional immediate-release prednisone, due to prednisone release which occurs prior to the circadian flare-up of IL-6 synthesis and inflammatory activity."

The study was sponsored by Merck Pharma GmbH and Nitec Pharma AG. Prof. Buttgerit and some of the coauthors said they had received consulting and grant funding from the companies. ■



Take on the
mealtime challenge

And help your patients improve glycemic control with NovoLog®, the #1 selling rapid-acting mealtime insulin.¹

Model is for illustrative purposes only.

NovoLog® is an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus.

Important safety information

NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients. NovoLog® has a more rapid onset and shorter duration of action than regular human insulin. An injection of NovoLog® should be immediately followed by a meal within 5 to 10 minutes. Because of the short duration of action of NovoLog®, a longer-acting insulin also should be used in patients with type 1 diabetes and may be needed in patients with type 2 diabetes. **When used in an external subcutaneous insulin infusion pump, NovoLog® should not be mixed with any other insulin or diluent.** Hypoglycemia is the most common adverse effect of all insulin therapies, including NovoLog®. The timing of hypoglycemia usually reflects the time-action profile of the administered insulins.

Any change of insulin dose should be made cautiously and only under medical supervision. Glucose monitoring is recommended for all patients with diabetes and is particularly important for patients using external pump infusion therapy. As with all insulin preparations, the time course of action of NovoLog® may vary in different individuals or at different times in the same individual and is dependent on many conditions, including injection site, local blood supply, temperature, and level of physical activity.

Severe, life-threatening generalized allergy, including anaphylactic reaction, may occur with any insulin product, including NovoLog®. Adverse reactions observed with NovoLog® include hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus. Insulin, particularly when given intravenously or in settings of poor glycemic control, may cause hypokalemia. Like all insulins, NovoLog® requirements may be reduced in patients with renal impairment or hepatic impairment.

To access complimentary e-learning programs, visit novomedlink.com/NovoLog.



Please see brief summary of Prescribing Information on adjacent page.

FlexPen® and NovoLog® are registered trademarks of Novo Nordisk A/S.
© 2009 Novo Nordisk Inc. 137970

June 2009



NovoLog®
insulin aspart (rDNA origin) injection